A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
An Open, Multicenter, Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of Tetra-specific Antibody GNC-038 Injection in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Sponsor: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
A PHASE1/PHASE2 clinical study on Primary Central Nervous System Lymphoma and Secondary Central Nervous System Lymphoma, this trial is ongoing. The trial is conducted by Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. and has accumulated 10 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Oct 2025 — Present [monthly]
Active Not Recruiting PHASE1/PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2025 — Oct 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Jul 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
▶ Show 5 earlier versions
-
Feb 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2023 — Feb 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2023 — Apr 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2022 — Feb 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
- Sichuan Baili Pharmaceutical Co., Ltd.
- SystImmune Inc.
For direct contact, visit the study record on ClinicalTrials.gov .